Gleicher, Norbert http://orcid.org/0000-0002-0202-4167
Darmon, Sarah K.
Molinari, Emanuela
Patrizio, Pasquale
Barad, David. H.
Funding for this research was provided by:
Center for Human Reproduction
The Foundation for Reproductive Medicine
Article History
Received: 11 November 2021
Accepted: 10 December 2021
First Online: 23 January 2022
Declarations
:
: This study was approved by the IRB of The CHR. All patients in this study signed an informed consent that allowed use of their medical record for research purposes if their identity was protected, and the material remained confidential. Since this study involved only use of deidentified electronic medical records, these conditions were met.
: Above noted approval also includes a consent for publication.
: N.G. and D.H.B. are listed as co-owners of several already awarded and still pending US patents, some claiming benefits from androgen supplementation in women with low functional ovarian reserve, a topic peripherally addressed in this manuscript. Others relate to diagnostic and potential therapeutic benefits of AMH, also marginally addressed in this manuscript. N.G. is a shareholder in Fertility Nutraceuticals, LLC, which produces a DHEA product, and is owner of The CHR., where much of the research reported in this manuscript was performed. N.G. and D.H.B. also receive patent royalties from Fertility Nutraceuticals, LLC. N.G., P.P., and D.H.B. also received research support, travel funding, and lecture fees from various Pharma and medical device companies, none, however, over the last 3 years and none in any way related to this manuscript. Other authors have no conflicts to report.